New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:23 EDTSNSS, DNDNSunesis appoints Joseph DePinto as Chief Commercial Officer
Sunesis Pharmaceuticals (SNSS) announced the appointment of Joseph DePinto to the newly created position of executive vice president and Chief Commercial Officer. Prior to joining Sunesis, DePinto was Executive Vice President, Global Commercial Operations at Dendreon (DNDN).
News For SNSS;DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:03 EDTSNSSSunesis announces EU patent covering vosaroxin, cytarabine combination
Sunesis Pharmaceuticals announced that the European Patent Office, or EPO, has granted European Patent No. 2 049 109 B1, claiming certain combined uses of vosaroxin and cytarabine, at doses of 10-120 mg/m2 and 5-1500 mg/m2, respectively, for the treatment of acute myelogenous leukemia and acute myeloblastic leukemia. The patent further provides for combinations of vosaroxin and cytarabine with other therapies, such as radiation, or other chemotherapeutics, including anti-cancer agents, in hematologic disorders, whether administered simultaneously or sequentially. Sunesis is proceeding to validate this patent in multiple EPO member states. The resulting national patents would expire in the third quarter of 2027, but could be eligible for supplementary patent term in EPO member states beyond this date. Related patent applications are pending in several countries, including the United States and Japan.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use